SOFT TISSUE SARCOMA
Clinical trials for SOFT TISSUE SARCOMA explained in plain language.
Never miss a new study
Get alerted when new SOFT TISSUE SARCOMA trials appear
Sign up with your email to follow new studies for SOFT TISSUE SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Direct cancer injection tested in early trial
Disease control TerminatedThis early-phase study tested a new treatment called BT-001, which is injected directly into tumors. It was given alone and combined with an existing immunotherapy drug (pembrolizumab) to people with advanced cancers that had spread. The main goals were to find a safe dose and se…
Matched conditions: SOFT TISSUE SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New combo attack on aggressive sarcomas
Disease control TerminatedThis early-stage study tested the safety of combining two chemotherapy drugs (gemcitabine and docetaxel) with radiation before surgery for adults with large, high-grade soft tissue sarcomas in their arms or legs. The main goal was to find the highest dose patients could tolerate …
Matched conditions: SOFT TISSUE SARCOMA
Phase: PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
First human test of new cancer drug halted
Disease control TerminatedThis early-stage study aimed to find a safe dose of a new drug called HFB301001 for adults with advanced cancers that had stopped responding to standard treatments. It involved 31 patients with cancers like sarcoma, kidney, liver, and melanoma. The trial was designed to test incr…
Matched conditions: SOFT TISSUE SARCOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Doctors ask: how do patients feel when cancer treatment returns?
Symptom relief TerminatedThis study aimed to understand how soft tissue sarcoma patients feel when they receive the same chemotherapy drug (trabectedin) for a second time. Researchers wanted to measure symptoms, side effects, and quality of life directly from patients during this retreatment. The study w…
Matched conditions: SOFT TISSUE SARCOMA
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Symptom relief
Last updated Mar 24, 2026 12:03 UTC